{"id":23879,"date":"2022-06-28T09:18:37","date_gmt":"2022-06-28T09:18:37","guid":{"rendered":"https:\/\/sagaciousresearch.com\/blog\/?p=23879"},"modified":"2023-03-28T10:15:29","modified_gmt":"2023-03-28T10:15:29","slug":"st26-sequence-listing-standard-easing-the-access-to-sequence-data","status":"publish","type":"post","link":"https:\/\/sagaciousresearch.com\/blog\/st26-sequence-listing-standard-easing-the-access-to-sequence-data","title":{"rendered":"ST26 Sequence Listing Standard: Easing the Access to Sequence Data"},"content":{"rendered":"\n

All patent applications disclosing nucleotide and\/or amino acid sequences must include sequence listings as per international filing standards. A new sequence listing standard \u2013 ST26 \u2013 is coming into force from July 1, 2022, that is expected to improve the data structure for automatic data exchange and verification between patent offices and biological sequence search databases. Although ST26 is a WIPO (World Intellectual Property Organization) initiative, the decision on how accessible the new sequence listings on public portals should be is in the hands of individual patent offices. The need for a new listing standard arose as the current standard, ST25, did not support automated validation and data exchange.<\/p>\n\n\n\n

This article will talk about the difference between ST25 and ST26, the shortcomings of ST25, the changes brought in by WIPO in the new standard, its benefits, and much more. But first, let us have a clear understanding of what exactly sequence listing is.<\/p>\n\n\n\n

\n

Table of Contents<\/p>\n